Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: A nested case-control study

Journal of the National Cancer Institute

Volumn 103, Issue 9, 2011, Pages 744-752

  Cuzick, Jack ^a   Warwick, Jane ^a   Pinney, Elizabeth ^a   Duffy, Stephen W ^a   Cawthorn, Simon ^c   Howell, Anthony ^d   Forbes, John F ^e   Warren, Ruth M L ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NORTH BRISTOL NHS TRUST   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DENSITY; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DENSITY; DOUBLE BLIND PROCEDURE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT RESPONSE;

EID: 79955758418     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr079     Document Type: Article

References (21)

1. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159-1169.
2. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Eng J Med. 2007;356(3):227-236. (Pubitemid 46143226)
3. Warner E, Lockwood G, Tritchler D, Boyd NF. The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classifcation. Cancer Detect Prev. 1992;16(1):67-72.
4. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148(5):337-347. (Pubitemid 351665464)
5. Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat. 2005;94(2):115-122. (Pubitemid 41547108)
6. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98(17):1204-1214. (Pubitemid 44390991)
7. Greendale GA, Reboussin BA, Slone S, Wasilauskus C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003;95(1):30-37. (Pubitemid 36124293)
8. Stuedal A, Ma H, Bjorndal H, Ursin G. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: fndings from a cross-sectional study among Norwegian women. Climacteric. 2009;12(3):248-258.
9. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev. 1999;8(10):863-866. (Pubitemid 29508720)
10. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst. 2004;96(8):621-628. (Pubitemid 38584986)
11. Kerlikowske K, Ichikawa L, Miglioretti DL, et al.; National Institutes of Health Breast Cancer Surveillance Consortium. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst. 2007;99(5):386-395. (Pubitemid 47073482)
12. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296-300. (Pubitemid 36126189)
13. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18): 1371-1388. (Pubitemid 28439961)
14. Cuzick J, Forbes J, Edwards R, et al.; IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817-824. (Pubitemid 35257944)
15. Cuzick J, Forbes JF, Sestak I, et al.; International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272-282. (Pubitemid 47073490)
16. Byng JW, Yaffe MJ, Jong RA, et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. RadioGraphics. 1998;18(6):1587-1598. (Pubitemid 128467077)
17. Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: an international consensus statement. Lancet Oncol. In press.
18. Cuzick J, Sestak I, Cella D, Fallowfeld L; ATAC Trialists' Group. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008;9(12):1143-1148.
19. Huang Y, Malone KE, Cushing-Haugen KL, Daling JR, Li CI. Relationship between menopausal symptoms and risk of postmenopausal breast cancer [published online ahead of print January 6, 2011]. Cancer Epidemiol Biomarkers Prev. 2011;20(2):379-388.
20. Gao J, Warren R, Warren-Forward H, Forbes JF. Reproducibility of visual assessment on mammographic density. Breast Cancer Res Treat. 2008;108(1):121-127. (Pubitemid 351623241)
21. Hattar R, Maller O, McDaniel S, et al. Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes [published online ahead of print January 27, 2009]. Breast Cancer Res. 2009;11(1):R5.